Which statement best describes the cardiovascular safety profile of CGRP antagonists?

Which statement best describes the cardiovascular safety profile of CGRP antagonists?

• A. They do not cause vasoconstriction, so they are safe in cardiovascular disease
• B. They cause vasoconstriction and are contraindicated in cardiovascular disease
• C. They are contraindicated in all patients with hypertension
• D. They have no effect on the vascular system

Answer: (A)

CGRP is a potent vasodilator in the cranial circulation, and blocking its receptor with CGRP antagonists prevents this vasodilation in the intracranial vessels. Because of this mechanism, these drugs do not provoke the kind of systemic vasoconstriction that is a concern with some migraine therapies (like triptans and ergot derivatives). Clinical data support a favorable cardiovascular safety profile, making them generally safe to use in patients with cardiovascular disease. So the statement that they do not cause vasoconstriction and are safe in cardiovascular disease aligns with their mechanism and observed safety, unlike the notion that they cause vasoconstriction or are contraindicated in hypertension. While no drug is without any risk, CGRP antagonists are not associated with significant vasoconstrictive effects in routine clinical use.

CGRP is a potent vasodilator in the cranial circulation, and blocking its receptor with CGRP antagonists prevents this vasodilation in the intracranial vessels. Because of this mechanism, these drugs do not provoke the kind of systemic vasoconstriction that is a concern with some migraine therapies (like triptans and ergot derivatives). Clinical data support a favorable cardiovascular safety profile, making them generally safe to use in patients with cardiovascular disease. So the statement that they do not cause vasoconstriction and are safe in cardiovascular disease aligns with their mechanism and observed safety, unlike the notion that they cause vasoconstriction or are contraindicated in hypertension. While no drug is without any risk, CGRP antagonists are not associated with significant vasoconstrictive effects in routine clinical use.